Smith Group Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Smith Group Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,404	Closed	-$29K	–	464
2014 Q1	$29K	Hold	1,404	–	–	﹤0.01%	287
2013 Q4	$28K	Hold	1,404	–	–	﹤0.01%	270
2013 Q3	$64K	Hold	1,404	–	–	﹤0.01%	233
2013 Q2	$33K	Buy	+1,404	New	+$22.4K	﹤0.01%	246

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

Smith Group Asset Management's STML Position: Q2 2014 in Review

Smith Group Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2014, closing a stake of 1,404 shares — an estimated $29K sold.

Smith Group Asset Management first reported a position in STML in Q2 2013 and held it in 4 quarters. The position peaked at $64K in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q2 2014.

Smith Group Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
Smith Group Asset Management sold 1,404 Stemline Therapeutics, Inc. shares in Q2 2014, an estimated $29K.
Smith Group Asset Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
Smith Group Asset Management's Stemline Therapeutics, Inc. position peaked at $64K in Q3 2013.
61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2014.

Based on Smith Group Asset Management's 13F filing for Q2 2014, filed 23 Jul 2014.